...Robert A. Baffi, Ph.D. to Its Board of Directors

Tue., June 15, 2021, 7:00 a.m

Experience in the Development of Biotechnology and Viral Based Therapeutics Will Help Enhance the Development of the Company's Pipeline

NOVATO, CA / ACCESSWIRE / June 15, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, today announced the election of Robert A. Baffi, Ph.D., to Mosaic's Board of Directors. Dr. Baffi most recently served as President of Global Manufacturing and Technical Operations at BioMarin Pharmaceutical Inc. (Nasdaq: BMRN).

"Dr. Baffi brings significant industry experience in the development of virus-based therapeutics. His experience in biomanufacturing, technical operations and drug development will be invaluable to Mosaic. Dr. Baffi's insight and skills have been an integral component of the growth and success of major biopharmaceutical companies for over three decades. His contributions to the development of drugs that have made a significant difference in patients' lives include more than 50 regulatory submissions of investigational new drugs and more than two dozen regulatory submissions for product approvals in the United States and abroad," said Steven King, president and chief executive officer of Mosaic. "We look forward to havingRobert's broad expertise and experience as we advance our programs."

"I am pleased to join the Mosaic team and to assist in its mission to develop therapies and vaccines to treat cancer and infectious diseases," said Dr. Robert Baffi. "Mosaic ImmunoEngineering has a very innovative and unique technology with broad potential and I look forward to helping the company bring their lead candidates into the clinic where they have potential to help patients with life threatening diseases."

Dr. Baffi served as president of global manufacturing and technical operations at BioMarin Pharmaceutical Inc., where he spent 20 years in various capacities overseeing the manufacturing, process development, quality, analytical chemistry, logistics and engineering departments. He established the technical operations infrastructure supporting the company's commercial production and distribution demands globally. Dr. Baffi developed innovative and successful chemistry manufacturing and controls strategies enabling the company to grow from research to commercialization.

Prior to BioMarin, Dr. Baffi served for over 14 years at Genentech, Inc., holding positions of enhanced leadership and responsibility within quality and technical operations. He developed key procedures, controls and strategies to support the approval, launch or continuing supply of 16 commercial biotechnology products. As the single point of contact between technical operations and business development, he created an alliance management framework to coordinate all aspects of research and corporate partnerships from due diligence to program execution.

Previously, Dr. Baffi worked for Cooper BioMedical as a research scientist and at Becton Dickinson Research Center as a post-doctoral fellow. He currently serves on the board for the National Institute for Bioprocessing Research and Training ("NIBRT") and Neurogene Inc. He has authored over a dozen publications and seven patents covering a diverse set of technologies. Dr. Baffi received a Ph.D., M. Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

About Mosaic ImmunoEngineering Inc.

etc etc

Forward-Looking Statements

etc etc

Contact: Jay Carlson
Sr. Manager, Investor Relations
Mosaic ImmunoEngineering Inc.
info@mosaicie.com

SOURCE: Mosaic ImmunoEngineering Inc

https://ca.finance.yahoo.com/news/mosaic-immunoengineering-inc-elects-biotechnology-110000059.html